Viewing nowCombinationEmpaglin Met Extended-Release Tablet 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkuk Pharmaceutical Co., Ltd.

MFDS item code 202501718 · Approved 2025.07.09 · Insurance code 653406070
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication contains both empagliflozin and metformin, which helps improve blood sugar control in adults with type 2 diabetes. It is administered as an adjunct to diet and exercise therapy to help manage blood sugar levels more effectively. In particular, patients with type 2 diabetes whose blood sugar is poorly controlled and who have cardiovascular disease need to be aware of the occurrence of cardiovascular events; therefore, it is important to refer to relevant clinical trial information for healthcare professionals. This medication is used to improve blood sugar control in patients.
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication is used to treat diabetes and helps lower blood sugar. However, it may rarely cause a serious condition called lactic acidosis, so caution is necessary. When used with other diabetes medications, the risk of hypoglycemia may increase, so care should be taken. Patients with moderate to severe renal impairment, acute kidney problems, heart failure, severe infections, or those scheduled for surgery should not use this medication. In addition, pregnant women and individuals with certain genetic disorders should not be administered this drug. During treatment with this medication, regular kidney function tests are advised, and patients should consult their physician immediately if conditions such as dehydration, severe vomiting, or diarrhea occur. Symptoms of hypoglycemia may appear, and dosage adjustments may be necessary when used in conjunction with insulin or other hypoglycemic agents. Urinary or genital infections may occur; thus, prompt treatment should be sought if symptoms of infection arise. Caution should be exercised when using this medication in patients with liver dysfunction, and it is advisable to avoid alcohol consumption. Prior to surgery or examinations using iodinated contrast agents, temporarily discontinue this medication, and ensure normal kidney function afterwards. It is safest not to use this drug during pregnancy or breastfeeding. Elderly patients or those with poor nutritional status should use this medication with particular caution, and in case of overdose, immediate treatment at a hospital is required. This medication should be swallowed whole without crushing, chewing, or splitting; the tablet shell may appear in the stool, which is normal.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, avoid storage in excessively hot or cold places and maintain a temperature between 1 to 30 degrees Celsius at room temperature.
Brown, oval-shaped, bilaterally convex extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkuk Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.